The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2
Open accessAbstract
The INK4a-ARF locus encodes two proteins, p16(INK4a) and p19(ARF), that restrain cell growth by affecting the functions of the retinoblastoma protein and p53, respectively. Disruption of this locus by deletions or point mutations is a common event in human cancer, perhaps second only to the loss of p53. Using insect cells infected with baculovirus vectors and NIH 3T3 fibroblasts infected with ARF retrovirus, we determined that mouse p19(ARF) can interact directly with p53, as well as with the p53 regulator mdm2. ARF can bind p53-DNA complexes, and it depends upon functional p53 to transcriptionally induce mdm2 and the cyclin-dependent kinase inhibitor p21(Cip1), and to arrest cell proliferation. Binding of p19(ARF) to p53 requires the ARF N-terminal domain (amino acids 1-62) that is necessary and sufficient to induce cell cycle arrest. Overexpression of p19(ARF) in wild type or ARF-null mouse embryo fibroblasts increases the half-life of p53 from 15 to approximately 75 min, correlating with an increased p53-dependent transcriptional response and growth arrest. Surprisingly, when overexpressed at supra-physiologic levels after introduction into ARF-null NIH 3T3 cells or mouse embryo fibroblasts, the p53 protein is handicapped in inducing this checkpoint response. In this setting, reintroduction of p19(ARF) restores p53's ability to induce p21(Cip1) and mdm2, implying that, in addition to stabilizing p53, ARF modulates p53-dependent function through an additional mechanism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Under most conditions ARF functions as a tumor suppressor by binding and inhibiting Mdm2 activity [47–49].”
From Integration of DNA damage and repair with murine double-minute 2 (Mdm2) in tumorigenesis (2012) · cites this paper as [47]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Recombinant Genomes Which Express Chloramphenicol Acetyltransferase in Mammalian Cells
Gorman, C., Moffat, L. F., & Howard, B. H. (1982) · Molecular and Cellular Biology · doi:10.1128/mcb.2.9.1044 · Cited by 7,674
High-Efficiency Transformation of Mammalian Cells by Plasmid DNA
Chen, C., & Okayama, H. (1987) · Molecular and Cellular Biology · doi:10.1128/mcb.7.8.2745 · Cited by 5,327
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Self-citationTodaro, G. J., & Green, H. (1963) · The Journal of Cell Biology · doi:10.1083/jcb.17.2.299 · Cited by 2,747
Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain
Gu, W., & Roeder, R. G. (1997) · Cell · doi:10.1016/s0092-8674(00)80521-8 · Cited by 2,559
DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
Shieh, S.-Y., Ikeda, M., Taya, Y., & Prives, C. (1997) · Cell · doi:10.1016/s0092-8674(00)80416-x · Cited by 2,100
Research works printed but not linked: 10
- M Hollstein, K Rice, M S Greenblatt, T Soussi, R Fuchs, T Sorlie, E Hovig, B Smith-Sorensen, R Montesano, C C Harris Nucleic Acids Res 22, 3551–3555 (1994).
- D Duro, O Bernard, V Della Valle, R Berger, C-J Larsen Oncogene 11, 21–29 (1995).
- L Mao, A Merlo, G Bedi, G I Shapiro, C D Edwards, B J Rollins, D Sidransky Cancer Res 55, 2995–2997 (1995).
- S Stone, P Jiang, P Dayananth, S V Tavtigian, H Katcher, D Parry, G Peters, A Kamb Cancer Res 55, 2988–2994 (1995).
- 10.1128/mcb.13.7.4107-4114.1993 · DOI
- P W Hinds, C A Finlay, R S Quartin, S J Baker, E R Fearon, B Vogelstein, A J Levine Cell Growth Diff 1, 571–580 (1990).
- 10.1128/mcb.7.8.2745-2752.1987 · DOI
- 10.1126/science.256.5058.827 · DOI
- 10.1128/mcb.2.9.1044-1051.1982 · DOI
- G Shaulsky, N Goldfinger, M S Tosky, A J Levine, V Rotter Oncogene 6, 2055–2065 (1991).
Cited by
Sorted by citations
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., Hahn, W. C., Ligon, K. L., Louis, D. N., Brennan, C., et al. (2007) · Genes & Development · doi:10.1101/gad.1596707 · Cited by 2,316
The first 30 years of p53: growing ever more complex.
Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967
Molecular mechanisms of drug resistance
Longley, D., & Johnston, P. (2005) · The Journal of Pathology · doi:10.1002/path.1706 · Cited by 1,726
Genetic Pathways to Primary and Secondary Glioblastoma
Ohgaki, H., & Kleihues, P. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.070011 · Cited by 1,487
Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells.
Lessard, J., & Sauvageau, G. (2003) · Nature · doi:10.1038/nature01572 · Cited by 1,452
The complexity of p53 modulation: emerging patterns from divergent signalsPreprint
Giaccia, A. J., & Kastan, M. B. (1998) · Genes & Development · doi:10.1101/gad.12.19.2973 · Cited by 1,315
Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization
Zindy, F., Eischen, C. M., Randle, D. H., Kamijo, T., Cleveland, J. L., Sherr, C. J., & Roussel, M. F. (1998) · Genes & Development · doi:10.1101/gad.12.15.2424 · Cited by 1,245
Self-citationMayo, L. D., & Donner, D. B. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.181181198 · Cited by 1,230
The Pezcoller lecture: cancer cell cycles revisited.
Sherr, C. J. (2000) · PubMed · Cited by 1,193
Self-citationForging a signature of in vivo senescence
Sharpless, N. E., & Sherr, C. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3960 · Cited by 1,104
Self-citationApoptosis and Molecular Targeting Therapy in Cancer
Hassan, M. K., Watari, H., Abu-Almaaty, A. H., Ohba, Y., & Sakuragi, N. (2014) · BioMed Research International · doi:10.1155/2014/150845 · Cited by 1,155
RetractedLinking the p53 tumour suppressor pathway to somatic cell reprogramming
Kawamura, T., Suzuki, J., Wang, Y. V., Menendez, S., Morera, L. B., Raya, A., Wahl, G. M., & Belmonte, J. C. I. (2009) · Nature · doi:10.1038/nature08311 · Cited by 1,115
Aguirre, A. J., Bardeesy, N., Sinha, M., Lopez, L., Tuveson, D. A., Horner, J., Redston, M. S., & DePinho, R. A. (2003) · Genes & Development · doi:10.1101/gad.1158703 · Cited by 1,033
The INK4a/ARF network in tumour suppression
Sherr, C. J. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35096061 · Cited by 1,001
Self-citationp53 and Human Cancer: The First Ten Thousand Mutations
Hainaut, P. L., & Hollstein, M. C. (1999) · Advances in cancer research · doi:10.1016/s0065-230x(08)60785-x · Cited by 999
Nucleolar Arf sequesters Mdm2 and activates p53
Weber, J. D., Taylor, L. J., Roussel, M. F., Sherr, C. J., & Bar-Sagi, D. (1999) · Nature Cell Biology · doi:10.1038/8991 · Cited by 940
Self-citationp53 ubiquitination: Mdm2 and beyond
Brooks, C. L., & Gu, W. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.020 · Cited by 924
Nevins, J. R. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.7.699 · Cited by 939
Rosenwald, A., Wright, G. W., Wiestner, A. U., Chan, W. C., Connors, J. M., Campo, E., Gascoyne, R. D., Grogan, T. M., Müller-Hermelink, H. K., Smeland, E. B., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00028-x · Cited by 913
Regulation of the INK4b–ARF–INK4a tumour suppressor locus: all for one or one for all
Gil, J., & Peters, G. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1987 · Cited by 843
Telomeres and telomerase in cancer
Artandi, S. E., & DePinho, R. A. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp268 · Cited by 823
Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis
Eischen, C. M., Weber, J. D., Roussel, M. F., Sherr, C. J., & Cleveland, J. L. (1999) · Genes & Development · doi:10.1101/gad.13.20.2658 · Cited by 819
Self-citationTuveson, D. A., Shaw, A. T., Willis, N. A., Silver, D. P., Jackson, E. L., Chang, S., Mercer, K. L., Grochow, R., Hock, H., Crowley, D., et al. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00085-6 · Cited by 798
The p53–Mdm2 module and the ubiquitin system
Michael, D., & Oren, M. (2002) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00099-8 · Cited by 772
Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation
Brooks, C. L., & Gu, W. J. (2003) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(03)00003-6 · Cited by 746
Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53
Honda, R., & Yasuda, H. (1999) · The EMBO Journal · doi:10.1093/emboj/18.1.22 · Cited by 724
Tumor surveillance via the ARF–p53 pathwayPreprint
Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.19.2984 · Cited by 718
Self-citationApoptosis, p53, and tumor cell sensitivity to anticancer agents.
Brown, J. M., & Wouters, B. G. (1999) · PubMed · Cited by 696
Sherr, C. J., & Weber, J. D. (2000) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)00038-6 · Cited by 654
Self-citationPrives, C. (1998) · Cell · doi:10.1016/s0092-8674(00)81774-2 · Cited by 623
Tumour suppression by p53: a role for the DNA damage response?
Meek, D. W. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2716 · Cited by 625
E1A signaling to p53 involves the p19ARFtumor suppressorPreprint
de Stanchina, E., McCurrach, M. E., Zindy, F., Shieh, S.-Y., Ferbeyre, G., Samuelson, A. V., Prives, C. L., Roussel, M. F., Sherr, C. J., & Lowe, S. W. (1998) · Genes & Development · doi:10.1101/gad.12.15.2434 · Cited by 611
Self-citationDivorcing ARF and p53: an unsettled case
Sherr, C. J. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1954 · Cited by 595
Self-citationThe cellular response to p53: the decision between life and death
Sionov, R. V., & Haupt, Y. (1999) · Oncogene · doi:10.1038/sj.onc.1203130 · Cited by 608
Regulation of the p53 Tumor Suppressor Protein
Oren, M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.51.36031 · Cited by 567
Molecular Interaction Map of the Mammalian Cell Cycle Control and DNA Repair Systems
Kohn, K. W. (1999) · Molecular Biology of the Cell · doi:10.1091/mbc.10.8.2703 · Cited by 561
Role of iron in carcinogenesis: cancer as a ferrotoxic disease
Toyokuni, S. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2008.01001.x · Cited by 552
ARF-BP1/Mule Is a Critical Mediator of the ARF Tumor Suppressor
Chen, D., Kon, N., Li, M., Zhang, W., Qin, J., & Gu, W. J. (2005) · Cell · doi:10.1016/j.cell.2005.03.037 · Cited by 551
P19 ARF stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2
Tao, W., & Levine, A. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.6937 · Cited by 539
The INK4A/ARF locus and its two gene products.
Sharpless, N. E., & DePinho, R. A. (1999) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)80004-5 · Cited by 533
twist is a potential oncogene that inhibits apoptosis
Maestro, R., Tos, A. P. D., Hamamori, Y., Krasnokutsky, S., Sartorelli, V., Kedes, L., Doglioni, C., Beach, D. H., & Hannon, G. J. (1999) · Genes & Development · doi:10.1101/gad.13.17.2207 · Cited by 516
Malignant melanoma: genetics and therapeutics in the genomic eraPreprint
Chin, L., Garraway, L. A., & Fisher, D. E. (2006) · Genes & Development · doi:10.1101/gad.1437206 · Cited by 524
Frank, K. M., Sharpless, N. E., Gao, Y., Sekiguchi, J., Ferguson, D. O., Zhu, C., Manis, J. P., Horner, J. W., DePinho, R. A., & Alt, F. W. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)80264-6 · Cited by 503
Melanoma: from mutations to medicine
Tsao, H., Chin, L., Garraway, L. A., & Fisher, D. E. (2012) · Genes & Development · doi:10.1101/gad.191999.112 · Cited by 496
The molecular basis of T cell acute lymphoblastic leukemia
Vlierberghe, P. V., & Ferrando, A. A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61269 · Cited by 489
Telomeres, stem cells, senescence, and cancer
Sharpless, N. E., & DePinho, R. A. (2004) · Journal of Clinical Investigation · doi:10.1172/jci20761 · Cited by 488
Distinct Thresholds Govern Myc's Biological Output In Vivo
Murphy, D. J., Junttila, M. R., Pouyet, L., Karnezis, A., Shchors, K., Bui, D. A., Brown-Swigart, L., Johnson, L., & Evan, G. I. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.10.018 · Cited by 456
Esteller, M., Tórtola, S., Toyota, M., Capellá, G., Peinado, M. A., Baylin, S. B., & Herman, J. G. (2000) · PubMed · Cited by 464
INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53
Schmitt, C. A., McCurrach, M. E., de Stanchina, E., Wallace-Brodeur, R. R., & Lowe, S. W. (1999) · Genes & Development · doi:10.1101/gad.13.20.2670 · Cited by 458
Myc pathways provoking cell suicide and cancer
Nilsson, J. A., & Cleveland, J. L. (2003) · Oncogene · doi:10.1038/sj.onc.1207261 · Cited by 470
The Developmental Biology of Brain Tumors
Wechsler‐Reya, R. J., & Scott, M. P. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.385 · Cited by 466
A nucleolar mechanism controlling cell proliferation in stem cells and cancer cellsPreprint
Tsai, R. Y. L., & McKay, R. D. G. (2002) · Genes & Development · doi:10.1101/gad.55671 · Cited by 449
Regulation of p53 function and stability by phosphorylation.
Ashcroft, M., Kubbutat, M. H. G., & Vousden, K. H. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.3.1751 · Cited by 452
The role of the E6-p53 interaction in the molecular pathogenesis of HPV
Thomas, M., Pim, D., & Banks, L. (1999) · Oncogene · doi:10.1038/sj.onc.1202953 · Cited by 448
INK4a/ARF: A multifunctional tumor suppressor locus
Sharpless, N. E. (2005) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2004.08.021 · Cited by 442
The genetics and mechanisms of T cell acute lymphoblastic leukaemia
Belver, L., & Ferrando, A. A. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.63 · Cited by 460
Itahana, K., Bhat, K., Jin, A., Itahana, Y., Hawke, D. H., Kobayashi, R., & Zhang, Y. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00431-3 · Cited by 431
Yin Yang 1 Is a Negative Regulator of p53
Sui, G., Affar, E. B., Shi, Y. G., Brignone, C., Wall, N. R., Yin, P., Donohoe, M., Luke, M. P.-S., Calvo, D., Grossman, S. R., et al. (2004) · Cell · doi:10.1016/j.cell.2004.06.004 · Cited by 433
ERK Activation Mediates Cell Cycle Arrest and Apoptosis after DNA Damage Independently of p53
Tang, D., Wu, D., Hirao, A., Lahti, J. M., Liu, L., Mazza, B., Kidd, V. J., Mak, T. W., & Ingram, A. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111598200 · Cited by 432
Kurki, S., Peltonen, K., Latonen, L., Kiviharju, T. M., Ojala, P. M., Meek, D. W., & Laiho, M. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00110-2 · Cited by 416
The MDM2-p53 pathway revisited
Nag, S. A., Jiangjiang, Q., Kalkunte, S. S., Ming-hai, W., & Zhang, R. (2013) · Journal of Biomedical Research · doi:10.7555/jbr.27.20130030 · Cited by 438
Ashcroft, M. A., & Vousden, K. H. (1999) · Oncogene · doi:10.1038/sj.onc.1203012 · Cited by 411
Dannenberg, J.-H., van Rossum, A., Schuijff, L., & te Riele, H. (2000) · Genes & Development · doi:10.1101/gad.847700 · Cited by 413
Drosophila p53 Is a Structural and Functional Homolog of the Tumor Suppressor p53
Ollmann, M. M., Young, L. M., Como, C. J. D., Karim, F. D., Belvin, M. P., Robertson, S., Whittaker, K. L., Demsky, M., Fisher, W. W., Buchman, A. R., et al. (2000) · Cell · doi:10.1016/s0092-8674(00)80626-1 · Cited by 420
The PTEN, Mdm2, p53 tumor suppressor–oncoprotein network
Mayo, L. D., & Donner, D. B. (2002) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(02)02166-7 · Cited by 419
Lang, F. F., Bruner, J. M., Fuller, G. N., Aldape, K., Prados, M. D., Chang, S. M., Berger, M. S., McDermott, M. W., Kunwar, S. M., Junck, L., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.21.13.2508 · Cited by 396
Iwakuma, T., & Lozano, G. (2003) · PubMed · Cited by 390
Pestell, R. G., Albanese, C., Reutens, A. T., Segall, J. E., Lee, R. J., & Arnold, A. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.4.0373 · Cited by 376
Short Dysfunctional Telomeres Impair Tumorigenesis in the INK4aΔ2/3 Cancer-Prone Mouse
Greenberg, R. A., Chin, L., Femino, A., Lee, K.-H., Gottlieb, G. J., Singer, R. H., Greider, C. W., & DePinho, R. A. (1999) · Cell · doi:10.1016/s0092-8674(00)80761-8 · Cited by 367
Jacobs, J. J. L., Keblusek, P., Robanus-Maandag, E., Kristel, P., Lingbeek, M., Nederlof, P. M., van Welsem, T., van de Vijver, M. J., Koh, E. Y., Daley, G. Q., et al. (2000) · Nature Genetics · doi:10.1038/81583 · Cited by 368
The MDM2 RING-finger domain is required to promote p53 nuclear export
Geyer, R. K., Yu, Z. K., & Maki, C. G. (2000) · Nature Cell Biology · doi:10.1038/35023507 · Cited by 361
Opposing Effects of Ras on p53
Ries, S., Biederer, C., Woods, D., Shifman, O., Shirasawa, S., Sasazuki, T., McMahon, M., Oren, M., & McCormick, F. (2000) · Cell · doi:10.1016/s0092-8674(00)00123-9 · Cited by 357
The inherent instability of mutant p53 is alleviated by Mdm2 or p16 INK4a lossPreprint
Terzian, T., Suh, Y., Iwakuma, T., Post, S. M., Neumann, M., Lang, G. A., Pelt, C. S. V., & Lozano, G. (2008) · Genes & Development · doi:10.1101/gad.1662908 · Cited by 363
Stress Signals Utilize Multiple Pathways To Stabilize p53
Ashcroft, M. A., Taya, Y., & Vousden, K. H. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.9.3224-3233.2000 · Cited by 360
p53-independent functions of the p19ARF tumor suppressorPreprint
Weber, J. D., Jeffers, J. R., Rehg, J. E., Randle, D. H., Lozano, G., Roussel, M. F., Sherr, C. J., & Zambetti, G. P. (2000) · Genes & Development · doi:10.1101/gad.827300 · Cited by 361
Self-citationZhang, Y., & Xiong, Y. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80351-2 · Cited by 347
p53 — a Jack of all trades but master of none
Junttila, M. R., & Evan, G. I. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2728 · Cited by 368
(1999) · PubMed · Cited by 338
Self-citationActivation of the p53 tumor suppressor protein
Vousden, K. H. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00035-5 · Cited by 337
The INK4 family of cell cycle inhibitors in cancer
Roussel, M. F. (1999) · Oncogene · doi:10.1038/sj.onc.1202998 · Cited by 331
Self-citationActivation and activities of the p53 tumour suppressor protein
Bálint, É., & Vousden, K. H. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2128 · Cited by 315
Photochemoprevention of ultraviolet B signaling and photocarcinogenesis
Afaq, F., Adhami, V. M., & Mukhtar, H. (2005) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2004.07.019 · Cited by 319
Epstein–Barr virus and Burkitt lymphoma
Brady, G., MacArthur, G. J., & Farrell, P. J. (2007) · Postgraduate Medical Journal · doi:10.1136/jcp.2007.047977 · Cited by 316
Mechanisms underlying hypoxia-induced neuronal apoptosis
Banasiak, K. J., Xia, Y., & Haddad, G. G. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00011-3 · Cited by 306
The genetics of malignant melanoma: lessons from mouse and man
Chin, L. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1145 · Cited by 312
Li, D., Marchenko, N. D., Schulz‐Heddergott, R., Fischer, V., Velasco-Hernández, T., Talos, F., & Moll, U. M. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0534 · Cited by 309
Feng, J., Tamaskovic, R., Yang, Z., Brazil, D. P., Merlo, A., Hess, D., & Hemmings, B. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404936200 · Cited by 294
Nucleophosmin (B23) Targets ARF to Nucleoli and Inhibits Its Function
Korgaonkar, C. K., Hagen, J., Tompkins, V. S., Frazier, A. A., Allamargot, C., Quelle, F. W., & Quelle, D. E. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.4.1258-1271.2005 · Cited by 294
Control of the cell cycle and apoptosis
Weinberg, R. A., & Lundberg, A. S. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00046-5 · Cited by 288
Ichimura, K., Bondesson, M., Goike, H., Schmidt, E., Moshref, A., & Collins, V. P. (2000) · PubMed · Cited by 282
Pouyan, A., Ghorbanlo, M., Eslami, M., Jahanshahi, M., Ziaei, E., Salami, A., Mokhtari, K., Shahpasand, K., Farahani, N., Meybodi, T. E., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02267-0 · Cited by 338
p16INK4A and p19ARF act in overlapping pathways in cellular immortalization
Carnero, A., Hudson, J. D., Price, C. M., & Beach, D. (2000) · Nature Cell Biology · doi:10.1038/35004020 · Cited by 280
Cooperative Signals Governing ARF-Mdm2 Interaction and Nucleolar Localization of the Complex
Weber, J. D., Kuo, M.-L., Bothner, B. B., DiGiammarino, E. L., Kriwacki, R. W., Roussel, M. F., & Sherr, C. J. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.7.2517-2528.2000 · Cited by 275
Self-citationCollado, M., Medema, R. H., Garcı́a-Cao, I., Dubuisson, M., Barradas, M., Glassford, J., Rivas, C., Burgering, B. M. T., Serrano, M., & Lam, E. W. ‐. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000759200 · Cited by 269
Unravelling the tumor-suppressive functions of FOXO proteins
Dansen, T. B., & Burgering, B. M. T. (2008) · Trends in Cell Biology · doi:10.1016/j.tcb.2008.07.004 · Cited by 271
Buschmann, T., Fuchs, S. Y., Lee, C.-G., Pan, Z., & Ronai, Z. A. (2000) · Cell · doi:10.1016/s0092-8674(00)80887-9 · Cited by 267
RetractedMao, H., LeBrun, D. G., Yang, J., Zhu, V. F., & Li, M. (2012) · Cancer Investigation · doi:10.3109/07357907.2011.630050 · Cited by 277
Aberrant Signaling Pathways in Glioma
Nakada, M., Kita, D., Watanabe, T., Hayashi, Y., Teng, L., Pyko, I. V., & Hamada, J. (2011) · Cancers · doi:10.3390/cancers3033242 · Cited by 277
A critical role for telomeres in suppressing and facilitating carcinogenesis
Artandi, S. E., & DePinho, R. A. (2000) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)00047-7 · Cited by 318
The INK4a/ARF locus and melanoma
Sharpless, N. E., & Chin, L. (2003) · Oncogene · doi:10.1038/sj.onc.1206461 · Cited by 260
Metadata
- Authors
- Kamijo, T., Weber, J. D., Zambetti, G., Zindy, F., Roussel, M. F., & Sherr, C. J.
- Affiliations
- St. Jude Children's Research Hospital (US)
- Howard Hughes Medical Institute and Departments of Tumor Cell Biology and Biochemistry, St. Jude Children’s Research Hospital, 332 North Lauderdale, Memphis, TN 38105
- Corresponding author
- Sherr, Charles J.
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 1998-07-07
- Volume
- 95
- Issue
- 14
- Pages
- 8292-8297
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC20969
- OpenAlex
- W2141529421
- Cited by
- 899
- References
- 61
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 2 · 2023: 10 · 2022: 11 · 2021: 15 · 2020: 10 · 2019: 10 · 2018: 12 · 2017: 14 · 2016: 26 · 2015: 21 · 2014: 33 · 2013: 28 · 2012: 34
- FWCI
- 31.09
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- St. Jude Children's Research Hospital (CA21765)
- American Lebanese Syrian Associated Charities (CA 21765)
- National Institutes of Health (CA21765))
- National Cancer Institute (R01CA063230, CA-71907, CA-63230, CA21765, P30CA021765, P01CA071907)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- p19ARF, p53, MDM2, INK4a/ARF locus, p16INK4a, protein-protein interaction, p53 stabilization, p21 Cip1, cell cycle arrest, p53-dependent transcription, tumor suppressor, p53 DNA binding, N-terminal domain
- MeSH terms
- Animals, Humans, Neoplasm Proteins, Nuclear Proteins, Proteins, Proto-Oncogene Proteins, Retroviridae, Transfection, Gene Expression Regulation, Neoplastic, Genes, Tumor Suppressor, Tumor Suppressor Protein p53, 3T3 Cells, Tumor Suppressor Protein p14ARF, Mice, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
